SCHEMBL589790

SCHEMBL589790

CC(NC(=O)c1cc(Cl)ccc1NC(=O)C1CC(Br)=NN1c1ncccc1Cl)C1CC1

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
F10 P00742 1/20 0.41
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MALT1 Q9UDY8 6/20 0.37
IDO1 P14902 3/20 0.37
NAMPT P43490 2/20 0.36
TRPV1 Q8NER1 2/20 0.36
GRM4 Q14833 1/20 0.35
RBP4 P02753 2/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL590447 0.91 F10 (0.41) F10NPC1RAB9AMALT1IDO1
SCHEMBL592361 0.88 IDO1 (0.37) F10NPC1RAB9AMALT1IDO1
SCHEMBL590823 0.88 MALT1 (0.41) F10NPC1RAB9AMALT1IDO1
SCHEMBL15085594 0.85 F10 (0.37) F10NPC1RAB9AMALT1IDO1
SCHEMBL15085552 0.85 F10 (0.37) F10NPC1RAB9AMALT1IDO1
SCHEMBL1148545 0.84 F10 (0.38) F10NPC1RAB9AMALT1IDO1
SCHEMBL1148147 0.84 F10 (0.38) F10NPC1RAB9AMALT1IDO1
SCHEMBL591382 0.84 CNR2 (0.45) MALT1TRPV1
SCHEMBL15085584 0.83 F10 (0.36) F10NPC1RAB9AMALT1IDO1
SCHEMBL15085600 0.83 F10 (0.37) F10NPC1RAB9AMALT1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2093223-B1 PROCESS AND INTERMEDIATES FOR PRODUCTION OF AN ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA (JP) 2013-08-21 EP disclosed
US-8481744-B2 Process for producing anthranilamide compound ISHIHARA SANGYO KAISHA, LTD. (JP) 2013-07-09 US disclosed
US-8481744-B2 Process for producing anthranilamide compound ISHIHARA SANGYO KAISHA, LTD. (JP) 2013-07-09 US disclosed
EP-2264021-B1 PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA (JP) 2013-06-26 EP disclosed
US-8115006-B2 Process for producing anthranilamide compound ISHIHARA SANGYO KAISHA, LTD. (JP) 2012-02-14 US disclosed
US-20110034696-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA, LTD. (JP) 2011-02-10 US disclosed
US-20110034696-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA, LTD. (JP) 2011-02-10 US disclosed
EP-2264021-A1 PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA, LTD. (JP) 2010-12-22 EP disclosed
US-20100063293-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA ,LTD. (JP) 2010-03-11 US disclosed
EP-2093223-A1 PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA, LTD. (JP) 2009-08-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063293-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND NAAA, AAAS, AADAC F10 1441/4885NPC1 4477/4885RAB9A 146/4885
US-20110034696-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND SQOR, NOX5, NOX3 F10 934/4885NPC1 4819/4885RAB9A 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.